Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysisShow others and affiliations
2018 (English)In: Diabetes, obesity and metabolism, ISSN 1462-8902, E-ISSN 1463-1326, Vol. 20, no 6, p. 1508-1514Article, review/survey (Refereed) Published
Abstract [en]
We conducted a systematic review and meta-analysis of observational studies investigating the association between antibiotic exposure in infancy and risk of childhood overweight and obesity. Thirteen studies, including a total of 527 504 children, were included in the systematic review and 8 were included in meta-analyses. Exposure to antibiotics in infancy was associated with an increased odds ratio (OR) of childhood overweight and obesity (OR 1.11, 95% confidence interval [CI] 1.02-1.20). Whereas exposure to 1 treatment only and exposure between 6 and 24 months were not associated with increased risk of childhood overweight and obesity, exposure to > 1 treatment was associated with an OR of 1.24 (95% CI 1.09-1.43) and exposure within the first 6 months of life was associated with an OR of 1.20 (95% CI 1.04-1.37). In conclusion, antibiotic exposure in infancy was associated with a slightly increased risk of childhood overweight and obesity, mainly if children were exposed to repeated treatments or treatment within the first 6 months of life. It is unclear whether this association is mediated via direct effects of antibiotics on the gut microbiota.
Place, publisher, year, edition, pages
John Wiley & Sons, 2018. Vol. 20, no 6, p. 1508-1514
Keywords [en]
anti-bacterial agents, body mass index, child, gastrointestinal microbiome, infant, meta-analysis, review
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-117538DOI: 10.1111/dom.13230ISI: 000431942800024PubMedID: 29359849Scopus ID: 2-s2.0-85042454412OAI: oai:DiVA.org:oru-117538DiVA, id: diva2:1917621
Funder
Novo Nordisk Foundation, NNF15OC0017740
Note
Funding information:
Danish Council for Independent Research |Medical Sciences (DFF – 6110-00075) and the Novo Nordisk Foundation (NNF15OC0017740).
2024-12-032024-12-032024-12-03Bibliographically approved